Atalar, BanuOzsahin, MahmutCall, JasonNapieralska, AleksandraKamer, SerraVilla, SalvadorErpolat, PetekNegretti, LauraLassen-Ramshad, YasminOnal, CemAkyurek, SerapUgurluer, GamzeBaumert, Brigitta G.Servagi-Vernat, StephanieMiller, Robert C.Ozyar, EnisSio, Terence T.2019-10-272019-10-2720180167-81401879-0887https://doi.org/10.1016/j.radonc.2017.12.028https://hdl.handle.net/11454/30522Background and purpose: The optimal treatment for adults with newly diagnosed medulloblastoma (MB) has not been defined. We report a large series of cases from the Rare Cancer Network. Material and methods: Thirteen institutions enrolled 206 MB patients who underwent postoperative radiotherapy (RT) between 1976 and 2014. Log-rank univariate and Cox-modeled multivariate analyses were used to analyze data collected. Results: Median patient age was 29 years; follow-up was 31 months. All patients had the tumor resected; surgery was complete in 140 (68%) patients. Postoperative RT was given in 202 (98%) patients, and 94% received craniospinal irradiation (CSI) and, usually, a posterior fossa boost. Ninety-eight (48%) patients had chemotherapy, mostly cisplatin and vincristine-based. The 10-year local control, overall survival, and disease-free survival rates were 46%, 51%, and 38%, respectively. In multivariate analyses, Karnofsky Performance Status (KPS) >= 80 and CSI were significant for disease-free and overall survival (P <= .04 for all); receiving chemotherapy and KPS >= 80 correlated with better local-control rates. Conclusions: Patients with high KPS who received CSI had better rates of disease-free and overall survival. Chemotherapy was associated with better local control. These results may serve as a benchmark for future studies designed to improve outcomes for adults with medulloblastoma. (C) 2018 Elsevier B. V. All rights reserved. Radiotherapy and Oncology 127 (2018) 96-102en10.1016/j.radonc.2017.12.028info:eu-repo/semantics/closedAccessAdult medulloblastomaChemotherapyCraniospinalMultimodalityRadiotherapyRare Cancer Network (RCN)Article127196102WOS:00043310200001529373196Q1Q1